Xeris Pharmaceuticals Inc. (XERS) Prices 9M Share Common Offering at $4.15/Sh

Xeris Pharmaceuticals, Inc. (NASDAQ: XERS), a specialty pharmaceutical company leveraging its novel technology platforms to develop and commercialize ready-to-use injectable and infusible drug formulations, today announced the pricing of an underwritten public offering of 9,000,000 shares of its common stock at a public offering price of $4.15 per share, before underwriting discounts and commissions and other offering expenses, for gross proceeds of approximately $37.4 million. All shares of common stock will be offered by Xeris. The Company has also granted the underwriters a 30-day option to purchase from the Company up to an additional 1,350,000 shares of common stock at the public offering price, less underwriting discounts and commissions. The offering is expected to close on February 14, 2020, subject to customary closing conditions.

Jefferies, Piper Sandler, RBC Capital Markets and Mizuho Securities are acting as joint book running managers for the offering.

You May Also Be Interested In

• Jefferies Assumes L3Harris Technologies (LHX) at Hold
• Greenland Mines prices $20M public offering of common stock
• CrowdStrike (CRWD) PT Raised to $260 at RBC Capital as 'AI threats accelerate ARR growth'